Cargando…
Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report
Docetaxel is the current first-line treatment for castration-resistant prostate cancer (CRPC), following failure to respond to maximal androgen blockade (MAB). Patients who fail to respond to docetaxel may receive cabazitaxel or abiraterone; however, there are no recommendations on which of these tw...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701088/ https://www.ncbi.nlm.nih.gov/pubmed/23833660 http://dx.doi.org/10.3892/ol.2013.1275 |